50 results about "Epigenome" patented technology

The present invention provides, inter alia, a method for generating a genome-wide epigenomic map, comprising a correlation between methylation variable CpG positions (MVP) and genomic DNA sample types. MVP are those CpG positions that show a variable quantitative level of methylation between sample types. Particular genomic regions of interest (ROI) provide preferred marker sequences that comprise multiple, and preferably proximate MVP, and that have novel utility for distinguishing sample types. The epigenic maps have broad utility, for example, in identifying sample types, or for distinguishing between and among sample types. In a preferred embodiment the epigenomic map is based on methylation variable regions (MVP) within the major histocompatibility complex (MHC), and has utility, for example, in identifying the cell or tissue source of a genomic DNA sample, or for distinguishing one or more particular cell or tissue types among other cell or tissue types. Analysis of epigenetic characteristics of one, or of a set of nucleic acid sequences, in the context of an inventive epigenomic map, allows for the determination of an origin of the nucleic acids.

The invention provides for methods for predicting age of a subject based on the epigenome of the subject.

Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with improved targeting range and enhanced on-target activity, and their use in genomic engineering, epigenomic engineering, base editing, genome targeting, genome editing, and in vitro diagnostics.

An organism development system includes: at least one neuromorphic device including multiple sets of hardware components that each store one or parameters of neuromorphic configuration data to implement a neuron of a neural network, wherein: the neural network is configured by neuromorphic configuration data to derive a proposed genome or epigenome of a new organism meant to have a sought-for trait, and the neuromorphic configuration data is generated by training the neural network with a usage data set that includes trait data indicative of a trait and biological data indicative of a genome for each of multiple organisms; a genome or epigenome printing device to print genetic/epigenetic material of the new organism based on the proposed genome or epigenome, respectively; and a trait detection device to detect an observed trait of the new organism following its at least its generation for incorporation back into the usage data set.

The invention relates to a drug discovering method based on epigenome and application of the drug discovering method, and belongs to the technical field of biological medicines. The invention starts from the basic principle of drug effects, DNA methylation chip data of a sample of a patient is combined to an intergenic interaction network, key pathogenic genes in a disease morbidity process is excavated by a revised PageRank algorithm, and therefore, potential drugs for treating diseases are found out according to a drug target corresponding relation. The method has the characteristics of solid theoretical basis, easiness in implementation and high efficiency, and has wide application prospect in drug discovery.

The present invention provides a process and method for preventing and/or treating protein based diseases, including, but not limited to: Alzheimer's and other amyloid based disease groups. This method recognizes correlative similarities across genomics, phenotypic and pharmacologic analytics and data to identify a list of existing compounds as high probability targets to act as inhibitors and/or stimulants close to a disease of interest. Pertinent genetic or epigenetic variances, or protein expression anomalies, are used to assemble a list of existing compounds through the use of artificial intelligence, machine learning and algorithmic relationships. This invention applies current genomic, phenotypic and pharmacological data to leverage data previously obtained in pursuit of other disease treatments. Accordingly, the current invention collapses cycle time to discovery and dramatically reduces costs. Through this system of active compounds created from tenuous relationships exhibits an elevated probability of success. Using a selection of algorithms that coordinate relationships including, but not limited to: genomic, epigenomic, phenotypic, protein dysregulation, cultural, pharmacological, etc., data, the present invention collapses cycle time of development and dramatically reduces costs by accessing data on target rich groups of previously tested abstractly related compounds.

A system and method for performing an analysis of a subject's genome, transcriptome and/or epigenome is described. The identities of a predetermined number of, such as ten or more, characteristics in the subject's genome, transcriptome and/or epigenome which are associated with one or more particular phenotype(s) or an increased risk of a particular phenotype are determined by performing an analytical technique upon a biological sample obtained from the subject. The amounts of any royalties or fees required for determination of the identities of one or more of the ten or more characteristics in the subject's genome, transcriptome and/or epigenome are determined via a computer. The amount of a fee charged for a determination of the identities of the ten or more characteristics in the subject's genome, transcriptome and/or epigenome are adjusted via a computer to reflect the amount of the determined royalties or fees and/or the amount of a fee for a future treatment of the subject. A database accessed during the method is also described.

Provided herein are methods and devices for accurate sequencing and detection of epigenetic information from template polynucleotides. Also provided are methods for long-range strand displacement amplification of polynucleotides, microfluidic devices with selectively permeable barriers for multistep processing, and methods for polynucleotide amplification using the microfluidic devices.

Methods and kits for preparing re-usable single cells are described. Cell components are anchored using a nano-scale scaffold to create a re-usable single cell. The nano-scale scaffold may be a polyacrylamide nano-scale scaffold. Methods to determine modifications of the genome, transcriptome, or epigenome are described.

The present invention concerns a construct for epigenomic modification of genes comprising the following components:

a) a Krüppel-associated box zinc finger protein or homologous,

b) a DNA region capable of binding to the target gene or homologous,

c) a human DNA methyltransferase DNMT3A or homologous and

d) a murine DNA methyltransferase Dnmt3L or homologous

whereby components a), b), c) and d) are linked to each other either directly or via at least one linker. The construct is a designer epigenome modifier which can be used to silence genes coding for a protein in leukocytes which avoids the internalization of HI viruses in immune cells.

The invention belongs to the technical field of protein engineering, and particularly relates to a truncated variant of CRISPR nuclease SpCas9 from streptococcus pyogenes and an application of the truncated variant. According to the truncated variant disclosed by the invention, CRISPR-Cas9(TSpCas9) nuclease belongs to a CRISPR-Cas9 system, has shearing activity equivalent to that of wild type CRISPR-Cas9 nuclease, and is obtained through the steps of cutting out 120 amino acids from the 180th to the 299th in an amino acid sequence of the wild type CRISPR-Cas9 nuclease and performing recombination; and the amino acid sequence of the wild type CRISPR-Cas9 nuclease is as shown in SEQID NO.7, or the CRISPR-Cas9 nuclease contains 90% of an amino acid sequence as shown in the SEQID NO.7, namely SEQID NO.15. The truncated variant can be used for genome editing, gene targeting, genome engineering, apparent genome engineering, gene therapy and in vitro diagnosis.

The present invention concerns a construct for epigenomic modification of genes that includes the following components:

a) a Krüppel-associated box zinc finger protein or homologous,

b) a DNA region capable of binding to the target gene or homologous,

c) a human DNA methyltransferase DNMT3A or homologous and

d) a murine DNA methyltransferase Dnmt3L or homologous

whereby components a), b), c) and d) are linked to each other either directly or via at least one linker. The construct is a designer epigenome modifier which can be used to silence genes coding for a protein in leukocytes which avoids the internalization of HI viruses in immune cells.

The invention provides a method for simultaneously detecting genomic DNA polymorphism and methylation. The method comprises the following steps: performing DNA fragmentation, and digesting the 3' endof the DNA fragment with DNA exonuclease; adding a dNTPs mixture containing 5-hydroxymethylcytosine deoxyribonucleotide, and performing completion the 3' end of the DNA fragment; performing bisulfiteconversion treatment on the modified DNA fragment and connecting an adaptor adapted to a high-throughput sequencing platform, and finally constructing a sequencing library by PCR amplification. By combining a double-end sequencing mode of the high-throughput sequencing platform, genomic DNA polymorphism and methylation detection can be performed simultaneously, and the goal of simultaneous detection of genome and epigenome is achieved.

The invention discloses a set of vector system for rice epigenome methylation/demethylation. The invention provides a set of vector system for rice epigenome demethylation. According to the system, DNA methylation variation is rapidly generated by randomly demethylating a rice genome. The system relates to the expression of rice OsALKBH DNA 6mA demethylase, resulting in a wide range of low methylation. The mutagenesis technique is of great significance to plants with important agricultural significance, which may result in differential expression of alleles that are generally silenced by DNA methylation, thereby revealing the application of previously hidden phenotypic variations.

Provided herein are methods and compositions for analyzing epigenetic modifications of genomes. The methods and compositions are suited for complete epigenome sequencing of any modification for which an antibody or an affinity binding agent has been developed. In one aspect, provided herein is a method for analyzing epigenetic modification of a genome. In some embodiments of aspects provided herein, the method further comprises sequencing a sequencing library to generate sequence reads, and assembling the sequence reads with aid of a positional barcode sequence information. In some embodiments of aspects provided herein, the method further comprises determining a location of at least two different epigenetic modifications of the nucleic acid. Another aspect of the present disclosure provides a kit for analyzing an epigenetic modification of a nucleic acid.

The invention provides application of single cell sequencing as a marker in preparation of a diagnostic primary sicca syndrome. The single cell sequencing is obtained by separating peripheral blood mononuclear cells through flow-type activated cells, and the primary sicca syndrome is mainly composed of NK cells, and then T cells and B cells. According to the single cell sequencing technology, a genome, a transcriptome, a proteome and an epigenome are sequenced on the single cell level, heterogeneity information among different cells can be obtained from a tissue sample, the advantages of being accurate, efficient, safe and reliable are achieved, and therefore the differential expression marker of the sicca syndrome is screened out on the cell level, and the defects of sicca syndrome diagnosis are overcome. The single cell sequencing is easy and convenient, special preparation and specific time are not needed, and a specimen can be collected anytime and anywhere. In addition, the advantages of being extremely small in trauma and high in sensitivity are achieved.